Abstract: SA-PO276
The Effect of Magnesium Supplementation on Albuminuria in Patient With Type 2 Diabetic Mellitus in Phramongkutklao Hospital: A Randomized Double-Blinded Controlled Trial
Session Information
- Diabetic Kidney Disease: Clinical - II
November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- 602 Diabetic Kidney Disease: Clinical
Authors
- Santhitisate, Sriladda, Phramongkutklao Hospital, Bangkok, Thailand
- Varothai, Narittaya, Phramongkutklao Hospital, Bangkok, Thailand
Background
Hypomagnesemia is associated with the development of microvascular complications including albuminuria in type 2 diabetes mellitus patients. It can also worsen glycemic control by promoting insulin resistance. Although there are several studies showed benefits of magnesium in patients with type 2 diabetes mellitus, there is no recommendation in recent guidelines that dietary mineral supplementation can improve outcomes in patients who do not have underlying deficiencies. This study was aimed to compare the effect of magnesium supplementation on albuminuria in type 2 diabetes mellitus patients.
Methods
This randomized double-blinded controlled trial included 26 patients who have moderately or severely increased albuminuria and normomagnesemia. Subjects were randomly divided in two groups to receive either 200 mg magnesium oxide or placebo daily for 6 months. Urine albumin-to-creatinine ratio, fasting plasma glucose, HbA1C, lipid profiles, kidney function were recorded at baseline and after the intervention. Magnesium intake was also assessed by 3-day food record.
Results
Every patients in this study had inadequate magnesium intake (lower than 30% of recommended daily allowance). Mean urine albumin-to-creatinine ratio were 143.61 +/- 115.87 mg/g in magnesium group and 466.36 +/- 989.28 mg/g in placebo group (p-value 0.247). Mean serum magnesium were 1.88 +/- 0.16 mg/dL in magnesium group and 1.77 +/- 0.10 mg/dL in placebo group (p-value 0.052). After 6-month treatment, there was no significant difference in degree of albuminuria between two groups (-47.48 +/- 89.05 vs 127.05 +/- 859.45, p-value 0.511). Fasting plasma glucose, HbA1C, lipid profiles and kidney function were also no significant differences except serum cholesterol level. Serum cholesterol were increased in both groups but significantly higher in placebo group (5.07 +/- 26.43 vs 24.25 +/- 18.68, p-value 0.049).
Conclusion
Magnesium supplementation showed no significant effect in albuminuria among patients with type 2 diabetes mellitus.